Creative Medical Technology Holdings, Inc. (CELZ) - 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K, dated October 22, 2024, details a material definitive agreement entered into by Creative Medical Technology Holdings, Inc. The transaction closed on October 23, 2024. The Company is incorporated in Nevada and its common stock trades on The Nasdaq Stock Market LLC under the symbol "CELZ".
Key Financial Metrics and Transaction Details
The Company executed a registered direct offering and a concurrent private placement. Key financial terms include:
- Shares Issued: 418,552 shares of Common Stock.
- Purchase Price: $4.42 per share.
- Net Proceeds: Approximately $1.6 million after deducting fees and estimated expenses.
- Use of Proceeds: Working capital and general corporate purposes.
- Warrants Issued: Warrants to purchase up to 837,104 shares of Common Stock at an exercise price of $4.42 per share.
- Placement Agent Fees: 8.0% cash fee of gross proceeds, reimbursement of up to $75,000 in out-of-pocket expenses, and warrants equal to 5.0% of the aggregate shares sold and underlying the private placement warrants.
Material Changes and Restrictions
The filing does not provide comparative financial data (revenue, profit, cash flow) as this is a transaction report rather than a periodic financial statement. Material changes include:
- Capital Structure: Immediate increase in outstanding shares and potential future dilution from warrants.
- Liquidity: Influx of approximately $1.6 million in net cash.
- Lock-Up Agreements: Directors and executive officers are restricted from selling securities for 90 days following the closing of the Offering.
- Issuance Restrictions: The Company is restricted from issuing additional shares or convertible securities for 90 days following stockholder approval of the warrant issuance.
Outlook, Risks, and Contingencies
Management Commentary: The Company utilized an effective Form S-3 registration statement filed on October 4, 2024, to facilitate the offering. Roth Capital Partners acted as the exclusive placement agent.
Contingencies: The warrants issued to investors will not be exercisable until the Company obtains stockholder approval for the issuance of the underlying shares, as required by Nasdaq Listing Rule 5635(d). Once approved, the warrants will be exercisable for five years.
Risks: The filing notes standard legal disclaimers regarding the legality of the offer in various jurisdictions and the potential for dilution to existing shareholders.
Key Facts for Investor Verification
- Verify the exact closing date and final net proceeds received (estimated at $1.6 million).
- Confirm the timeline for the required stockholder vote to approve the warrant issuance.
- Review the full terms of the Warrants and Placement Agent Warrants filed as Exhibits 4.1 and 4.2.
- Monitor the impact of the 90-day lock-up period on insider trading activity.
- Assess the Company's cash burn rate to determine the runway provided by the $1.6 million in new capital.